Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation.
Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation.
复制标题
DOI:
10.15252/emmm.202012308
复制
发表时间:
2020-09-07
影响因子:
11.1
通讯作者:
Franzmeier N
中科院分区:
文献类型:
--
作者:
Ewers M;Biechele G;Suárez-Calvet M;Sacher C;Blume T;Morenas-Rodriguez E;Deming Y;Piccio L;Cruchaga C;Kleinberger G;Shaw L;Trojanowski JQ;Herms J;Dichgans M;Alzheimer's Disease Neuroimaging Initiative (ADNI);Brendel M;Haass C;Franzmeier N
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease (AD). Both cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of microglia activation, and microglia PET are increased in AD; however, whether an increase in these biomarkers is associated with reduced amyloid‐beta (Aβ) accumulation remains unclear. To address this question, we pursued a two‐pronged translational approach. Firstly, in non‐demented and demented individuals, we tested CSF sTREM2 at baseline to predict (i) amyloid PET changes over ∼2 years and (ii) tau PET cross‐sectionally assessed in a subset of patients. We found higher CSF sTREM2 associated with attenuated amyloid PET increase and lower tau PET. Secondly, in the App NL‐G-F mouse model of amyloidosis, we studied baseline 18F‐GE180 microglia PET and longitudinal amyloid PET to test the microglia vs. Aβ association, without any confounding co‐pathologies often present in AD patients. Higher microglia PET at age 5 months was associated with a slower amyloid PET increase between ages 5‐to‐10 months. In conclusion, higher microglia activation as determined by CSF sTREM2 or microglia PET shows protective effects on subsequent amyloid accumulation. TREM2 is a protein almost exclusively expressed by microglia in the brain. This study investigates the association between soluble TREM2 (sTREM2) levels in cerebrospinal fluid and the longitudinal Aβ accumulation in human and mouse.
登录
查看更多内容
DOI:
10.1056/nejmoa1211851
发表时间:
2013-01-10
期刊:
The New England journal of medicine
影响因子:
--
作者:
Guerreiro R;Wojtas A;Bras J;Carrasquillo M;Rogaeva E;Majounie E;Cruchaga C;Sassi C;Kauwe JS;Younkin S;Hazrati L;Collinge J;Pocock J;Lashley T;Williams J;Lambert JC;Amouyel P;Goate A;Rademakers R;Morgan K;Powell J;St George-Hyslop P;Singleton A;Hardy J;Alzheimer Genetic Analysis Group
通讯作者:
Alzheimer Genetic Analysis Group
影响因子:
14.5
作者:
Hamelin, Lorraine;Lagarde, Julien;Sarazin, Marie
通讯作者:
Sarazin, Marie
影响因子:
15.1
作者:
Bemiller SM;McCray TJ;Allan K;Formica SV;Xu G;Wilson G;Kokiko-Cochran ON;Crish SD;Lasagna-Reeves CA;Ransohoff RM;Landreth GE;Lamb BT
通讯作者:
Lamb BT
影响因子:
11
作者:
Brendel, M.;Jaworska, A.;Rominger, A.
通讯作者:
Rominger, A.
影响因子:
9.3
作者:
Blume T;Focke C;Peters F;Deussing M;Albert NL;Lindner S;Gildehaus FJ;von Ungern-Sternberg B;Ozmen L;Baumann K;Bartenstein P;Rominger A;Herms J;Brendel M
通讯作者:
Brendel M